|
- nubia M153 with Doubao AI Assistant is the true AI-native phone that brings an "autopilot" experience to the AI phone
- AI Pet iMoochi redefines emotional companionship with lifelike interactions, a furry, cloud-soft design and evolving personalities
BARCELONA, Spain, March 3, 2026 /PRNewswire/ -- ZTE Corporation, a global leading provider of integrated information and communication technology solutions, showcased its expanded portfolio of AI devices designed for a new era of interaction at MWC Barcelona 2026. Taking center stage were two groundbreaking innovations: nubia M153 with Doubao AI Assistant, which saw a limited launch in the Chinese market in December, and AI Pet iMoochi. These two devices represent a major leap forward for ZTE's "AI for All" strategy, driving the evolution of personal smart devices and accelerating the advancement of a Full-Scenario AI Ecosystem.
As An "AI-Native Phone Pioneer", nubia M153 with Doubao AI Assistant Defines A True "Autopilot" Experience
As an AI-Native Phone Pioneer, nubia is leading cutting-edge AI technology innovation and commercial adoption with its "Innovation + Action" approach. By deeply integrating AI across hardware, software, and its wider ecosystem, nubia is reshaping the paradigm of human-device interaction, working to transform AI from a mere tool into an agentic, symbiotic partner that understands and grows with you. nubia M153 with Doubao AI Assistant is the true AI-native phone that brings an "autopilot" experience to the AI phone powered by its OS-level Agent capabilities.
nubia M153 with Doubao AI Assistant is the outcome of an in-depth collaboration between Doubao and nubia at the OS level, capable of understanding and executing complex user commands in natural language, enabling cross-application task execution. This marks a paradigm shift from "users operating their phones" to "AI autonomously handling tasks for them". By seamlessly executing multi-step workflows, it delivers a highly natural and intuitive interaction. Whether booking a restaurant or comparing prices across platforms, a single voice command is all it takes. The phone then autonomously navigates necessary apps to handle the entire process from searching, comparing, booking and mapping the route.
nubia M153 with Doubao AI Assistant is built on a solid hardware foundation to support its advanced AI capabilities. It is powered by Snapdragon® 8 Elite Mobile Platform, coupled with 16GB of RAM and 512GB of storage, ensuring smooth AI computing and multitasking.
Designed to collaboratively refine AI experiences with developers and tech enthusiasts, nubia M153 with Doubao AI Assistant saw a limited launch in the Chinese market on December 1, 2025.
The New AI Species iMoochi Redefines Emotional Companionship
Designed to be a warm, understanding emotional companion. iMoochi features a furry, cloud-soft texture and soulful eyes. Its true magic lies in its rich, multi-modal interactions. Moving past mechanical dialogue, iMoochi utilizes a unique "iMoochi language" and distinctive "milky coos" to deliver a natural, comforting interactive experience. Through gentle haptic feedback and tactile sensors, a simple pat on the head or prolonged caressing results in loving nuzzling, joyful coos, and delighted tail wags. Operating on its own lifelike rhythm, iMoochi lives in its "own little world", it yawns when sleepy, feels hunger, senses temperature changes, and even reacts to the feeling of weightlessness when playfully tossed in the air.
iMoochi is perfect for users seeking stress relief, particularly young urban professionals, animal lovers unable to keep real pets, or families looking for a shared interactive bond. A dedicated companion app deepens this friendship by allowing users to name their iMoochi, check its mood, and read its personal diary, making the companionship feel valued. The iMoochi family features five distinct members: Hopami, Mimiu, Cynomi, Mogogo and Morin.
Whether reshaping human-device interaction with nubia M153 with Doubao AI Assistant, or defining a new category with AI Pet iMoochi, ZTE's lineup at MWC 2026 brings its "AI for All" strategy to life.
For more information, please visit the ZTE booth (3F30, Hall 3, Fira Gran Via) at MWC Barcelona 2026 or explore: https://www.zte.com.cn/global/about/exhibition/mwc26.html
MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: ZTE.press.release@zte.com.cn
- nubia M153 with Doubao AI Assistant is the true AI-native phone that brings an "autopilot" experience to the AI phone
- AI Pet iMoochi redefines emotional companionship with lifelike interactions, a furry, cloud-soft design and evolving personalities
BARCELONA, Spain, March 3, 2026 /PRNewswire/ -- ZTE Corporation, a global leading provider of integrated information and communication technology solutions, showcased its expanded portfolio of AI devices designed for a new era of interaction at MWC Barcelona 2026. Taking center stage were two groundbreaking innovations: nubia M153 with Doubao AI Assistant, which saw a limited launch in the Chinese market in December, and AI Pet iMoochi. These two devices represent a major leap forward for ZTE's "AI for All" strategy, driving the evolution of personal smart devices and accelerating the advancement of a Full-Scenario AI Ecosystem.
As An "AI-Native Phone Pioneer", nubia M153 with Doubao AI Assistant Defines A True "Autopilot" Experience
As an AI-Native Phone Pioneer, nubia is leading cutting-edge AI technology innovation and commercial adoption with its "Innovation + Action" approach. By deeply integrating AI across hardware, software, and its wider ecosystem, nubia is reshaping the paradigm of human-device interaction, working to transform AI from a mere tool into an agentic, symbiotic partner that understands and grows with you. nubia M153 with Doubao AI Assistant is the true AI-native phone that brings an "autopilot" experience to the AI phone powered by its OS-level Agent capabilities.
nubia M153 with Doubao AI Assistant is the outcome of an in-depth collaboration between Doubao and nubia at the OS level, capable of understanding and executing complex user commands in natural language, enabling cross-application task execution. This marks a paradigm shift from "users operating their phones" to "AI autonomously handling tasks for them". By seamlessly executing multi-step workflows, it delivers a highly natural and intuitive interaction. Whether booking a restaurant or comparing prices across platforms, a single voice command is all it takes. The phone then autonomously navigates necessary apps to handle the entire process from searching, comparing, booking and mapping the route.
nubia M153 with Doubao AI Assistant is built on a solid hardware foundation to support its advanced AI capabilities. It is powered by Snapdragon® 8 Elite Mobile Platform, coupled with 16GB of RAM and 512GB of storage, ensuring smooth AI computing and multitasking.
Designed to collaboratively refine AI experiences with developers and tech enthusiasts, nubia M153 with Doubao AI Assistant saw a limited launch in the Chinese market on December 1, 2025.
The New AI Species iMoochi Redefines Emotional Companionship
Designed to be a warm, understanding emotional companion. iMoochi features a furry, cloud-soft texture and soulful eyes. Its true magic lies in its rich, multi-modal interactions. Moving past mechanical dialogue, iMoochi utilizes a unique "iMoochi language" and distinctive "milky coos" to deliver a natural, comforting interactive experience. Through gentle haptic feedback and tactile sensors, a simple pat on the head or prolonged caressing results in loving nuzzling, joyful coos, and delighted tail wags. Operating on its own lifelike rhythm, iMoochi lives in its "own little world", it yawns when sleepy, feels hunger, senses temperature changes, and even reacts to the feeling of weightlessness when playfully tossed in the air.
iMoochi is perfect for users seeking stress relief, particularly young urban professionals, animal lovers unable to keep real pets, or families looking for a shared interactive bond. A dedicated companion app deepens this friendship by allowing users to name their iMoochi, check its mood, and read its personal diary, making the companionship feel valued. The iMoochi family features five distinct members: Hopami, Mimiu, Cynomi, Mogogo and Morin.
Whether reshaping human-device interaction with nubia M153 with Doubao AI Assistant, or defining a new category with AI Pet iMoochi, ZTE's lineup at MWC 2026 brings its "AI for All" strategy to life.
For more information, please visit the ZTE booth (3F30, Hall 3, Fira Gran Via) at MWC Barcelona 2026 or explore: https://www.zte.com.cn/global/about/exhibition/mwc26.html
MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: ZTE.press.release@zte.com.cn
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
As an AI-Native Phone Pioneer, nubia Reshapes the Paradigm of Human-Device Interaction at MWC Barcelona 2026
|
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
HiRO's Founder and CEO, Dr. Karen Chu, was a featured speaker at RESI JPM, where she moderated a panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified partnership models that accelerate progress, and outlined where capital is flowing in this rapidly advancing field.
Dr. Chu also led a workshop titled "Leveraging Asia: How to Navigate Asian VC Investment Mandates." The session opened with the 2026 industry outlook and key trends, then highlighted priority therapeutic areas. It explained the NewCo model and the criteria Asian venture capital firms use to evaluate global biotech assets, their co‑investment preferences, and expectations for commercialization. The workshop featured Asia‑based investors Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group; Jayson Lee, Partner and Head of Healthcare Investing, LongRiver Investments; and Dr. Maomeng Tong, Principal, INCE Capital, who shared strategic insights for biotechs pursuing cross‑border capital or collaboration.
"Asia's steady capital recovery is fueling more diverse, higher-quality biotech deals. Investors are increasingly favoring more scalable, capital-efficient, innovative business models. One such emerging approach is the NewCo model, which combines equity participation with experienced management teams, leverages Asia's efficient clinical speed and ecosystem partners to accelerate data generation, and enables program-level co-development. These elements de-risk global development in multiple ways, making the opportunities more attractive for international syndicates," said Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group.
"Clinical development now spans multiple regions more than ever and requires an integrated strategy. HiRO's cross‑border capabilities across APAC, the US, and Europe allow us to align regulatory strategy, site selection, and operational execution to bridge data across regions, accelerate timelines, and reduce redundant costs. By leveraging local expertise, regional cost advantages, and selective partnerships, we help biotech sponsors generate earlier, higher‑quality readouts and deploy capital more efficiently to advance financing and licensing goals," said Dr. Karen Chu, Founder and CEO of HiRO.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
HiRO's Founder and CEO, Dr. Karen Chu, was a featured speaker at RESI JPM, where she moderated a panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified partnership models that accelerate progress, and outlined where capital is flowing in this rapidly advancing field.
Dr. Chu also led a workshop titled "Leveraging Asia: How to Navigate Asian VC Investment Mandates." The session opened with the 2026 industry outlook and key trends, then highlighted priority therapeutic areas. It explained the NewCo model and the criteria Asian venture capital firms use to evaluate global biotech assets, their co‑investment preferences, and expectations for commercialization. The workshop featured Asia‑based investors Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group; Jayson Lee, Partner and Head of Healthcare Investing, LongRiver Investments; and Dr. Maomeng Tong, Principal, INCE Capital, who shared strategic insights for biotechs pursuing cross‑border capital or collaboration.
"Asia's steady capital recovery is fueling more diverse, higher-quality biotech deals. Investors are increasingly favoring more scalable, capital-efficient, innovative business models. One such emerging approach is the NewCo model, which combines equity participation with experienced management teams, leverages Asia's efficient clinical speed and ecosystem partners to accelerate data generation, and enables program-level co-development. These elements de-risk global development in multiple ways, making the opportunities more attractive for international syndicates," said Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group.
"Clinical development now spans multiple regions more than ever and requires an integrated strategy. HiRO's cross‑border capabilities across APAC, the US, and Europe allow us to align regulatory strategy, site selection, and operational execution to bridge data across regions, accelerate timelines, and reduce redundant costs. By leveraging local expertise, regional cost advantages, and selective partnerships, we help biotech sponsors generate earlier, higher‑quality readouts and deploy capital more efficiently to advance financing and licensing goals," said Dr. Karen Chu, Founder and CEO of HiRO.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
